Bausch & Lomb Inc. has received U.S. Food and Drug Administration approval for its Trulign lens, company officials said Tuesday.
Meant for cataract and other eye-surgery patients, the Trulign lens corrects astigmatic blurred vision, which can be an unwanted side effect of artificial lens implantation. According to the eye-care company, it is the first toric intraocular lens that can correct astigmatism and deliver improved vision across a natural range of focus as well.
(c) 2013 Rochester Business Journal. To obtain permission to reprint this article, call 585-546-8303 or e-mail email@example.com.